For instance, in GIST patients whose tumors harbor gain-of-function point mutations in the exon 11 JM domain of c-kit, found in 75-80% of the cases, imatinib provides a robust initial clinical response [71]. Here, KIT is linked to gastrointestinal stromal tumor.